Stock PHM PHARMA MAR, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Company Pharma Mar, S.A.

Equities

PHM

ES0169501022

Pharmaceuticals

Market Closed - BME
Other stock markets
 11:35:21 2024-04-16 am EDT 		After market 03:59:59 pm
26.54 EUR -2.07% Intraday chart for Pharma Mar, S.A. 26.63 +0.34%
Feb. 29 Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
Feb. 28 Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.

Number of employees: 509

Sales per Business

EUR in Million2022Weight2023Weight Delta
Oncology
99.2 %
191 97.4 % 157 99.2 % -17.96%
Diagnostics
0.8 %
5 2.6 % 1 0.8 % -76.79%
RNAi
0.1 %
0 0.0 % 0 0.1 % +290.32%

Sales per region

EUR in Million2022Weight2023Weight Delta
Ireland
47.6 %
87 44.2 % 75 47.6 % -13.17%
France
19.0 %
17 8.9 % 30 19.0 % +72.54%
Other
8.6 %
13 6.7 % 14 8.6 % +4.17%
United States
7.9 %
13 6.8 % 13 7.9 % -6.40%
Rest of the European Union
6.9 %
19 9.6 % 11 6.9 % -42.40%
Spain
4.4 %
17 8.5 % 7 4.4 % -58.36%
Germany
2.9 %
15 7.6 % 5 2.9 % -69.05%
Italy
2.6 %
15 7.7 % 4 2.6 % -72.40%

Managers

Managers TitleAgeSince
José Maria Fernández de Sousa-Faro CEO
 Chief Executive Officer - 86-04-29
Maria Luisa de Francia Caballero DFI
 Director of Finance/CFO - 87-12-31
Jose Maria Jimeno CTO
 Chief Tech/Sci/R&D Officer - -
Luis Rupérez Cuenca CTO
 Chief Tech/Sci/R&D Officer - 02-12-31
Sandra Llamera Sánchez CMP
 Compliance Officer - 20-03-31
Ali Zeaiter CTO
 Chief Tech/Sci/R&D Officer 47 17-12-31
Carmen Cuevas Marchante CTO
 Chief Tech/Sci/R&D Officer - 96-12-31
Nadia Badri CTO
 Chief Tech/Sci/R&D Officer - 10-12-31
José Luis Moreno Martinez-Losa IRC
 Investor Relations Contact - 14-12-31
Juan Nogués Ortuño SAM
 Sales & Marketing - 12-02-29

Members of the board

Members of the board TitleAgeSince
José Maria Fernández de Sousa-Faro CEO
 Chief Executive Officer - 86-04-29
Pedro Fernández Puentes BRD
 Director/Board Member - 86-04-29
Montserrat Andrade Detrell BRD
 Director/Board Member - -
Carlos Solchaga Catalán BRD
 Director/Board Member 79 -
Eduardo Serra Rexach BRD
 Director/Board Member 78 -
Blanca Hernández Rodríguez BRD
 Director/Board Member - 19-06-24
Rosa María Sánchez-Yebra Alonso BRD
 Director/Board Member - 22-06-28
Mera Ortega BRD
 Director/Board Member - -
Mariano Esteban Rodríguez BRD
 Director/Board Member - 22-06-28
Emiliano Calvo Aller BRD
 Director/Board Member - 22-06-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 18,354,907 13,712,564 ( 74.71 %) 715,000 ( 3.895 %) 74.71 %

Shareholders

NameEquities%Valuation
José Maria Fernández de Sousa-Faro
6.005 %
1,114,147 6.005 % 35 M €
Montserrat Andrade Detrell
5.144 %
954,460 5.144 % 30 M €
Pedro Fernández Puentes
4.948 %
917,979 4.948 % 28 M €
PHARMA MAR, S.A.
3.515 %
652,235 3.515 % 20 M €
RWC Asset Management LLP
1.059 %
196,406 1.059 % 6 M €
BNP PARIBAS ASSET MANAGEMENT Netherlands NV
0.3005 %
55,753 0.3005 % 2 M €
Caixabank Asset Management SGIIC SA
0.2286 %
42,416 0.2286 % 1 M €
Argenta Spaarbank NV
0.1450 %
26,897 0.1450 % 834 861 €
Fideuram Asset Management (Ireland) DAC
0.0899 %
16,678 0.0899 % 517 672 €
Consultinvest Asset Management SGR SpA
0.0833 %
15,448 0.0833 % 479 494 €

Holdings

NameEquities%Valuation
PHARMA MAR, S.A.
3.52%
 652,235 3.52% 20,244,853 $

Company contact information

Pharma Mar SA

Avenida de los Reyes, 1 Polígono Industrial La Mina

28770, Colmenar Viejo

+34 91 846 60 00

http://www.pharmamar.com
address Pharma Mar, S.A.(PHM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Pharma Mar, S.A.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
27.1 EUR
Average target price
49.4 EUR
Spread / Average Target
+82.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
PHARMA MAR, S.A. Stock Pharma Mar, S.A.
-35.39% 508M
CSL LIMITED Stock CSL Limited
-4.17% 86.99B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+4.34% 40.68B
BIOGEN INC. Stock Biogen Inc.
-24.14% 28.61B
UCB Stock UCB
+51.27% 24.1B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.61% 17.37B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-32.11% 13.72B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-5.10% 12.49B
INCYTE CORPORATION Stock Incyte Corporation
-14.80% 12B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-3.22% 7.94B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. PHM Stock
  4. Company Pharma Mar, S.A.